You Need to Know About This As It Just Starts to Hit the Mainstream

Please do not reply to this message, as replies are routed to an unmonitored mailbox. You are receiving this email as a part of your subscription to Cannabis Profits Daily. If you have any questions or would like to change your email settings, please reference the contact information at the bottom of this email.

Dear Reader, At Cannabis Profits Daily, we believe it is critical to bring you analysis on the most important trends in cannabis before they hit and companies in that space go from upstarts to known profit-makers with an expensive stock. Now, it's not every day that a type of product comes along with the ability to disrupt a trillion-dollar industry, like pharmaceuticals. CBD (cannabidiol) is starting its march to do just that. CBD is the most used of the non-psychoactive compounds in cannabis. It can create much of the effect found in pharmaceutical-grade products or things containing the compound within the cannabis plant that gets users high (THC) - all without a prescription, without impairment, and at a comparatively modest cost. Here and in my paid services within the National Institute of Cannabis Investors, I've been crystal clear about the massive potential for CBD. I'm confident that this non-regulated space represents the biggest opportunity of all when it comes to cannabis. And I'm only recently starting to get some lofty company: The New York Times recently wrote a piece so positive that, at one point, it likened CBD to the discovery of oxygen. Coca-Cola Co. was kicking the tires with one of Canada's biggest cannabis companies of late over possibly creating a CBD-infused beverage. And research firm Brightfield Group projects that the mainstreaming of hemp-based CBD will grow from $519 million in 2018 to an incredible $22 billion by 2022. That's why I've written the research report Prescription-Free CBD: Disrupting the $1.1 Trillion Pharmaceutical Industry. As a part of Cannabis Profits Daily and NICI, it's available to you now at no cost, along with several other research reports my team and I have worked hard to complete. You'll find out much more on why I'm bullish on CBD as well as some key differences between hemp and cannabis. Just click right here to read the details. You're clearly interested in taking part in cannabis investing, the greatest investment opportunity of our lifetime - getting educated on CBD is a must. Thanks for being an important part of the National Institute for Cannabis Investors, Greg Miller Executive Director, National Institute for Cannabis Investors P.S.: I'll be back soon to talk about a topic near-and-dear to me and my colleagues tomorrow: veterans and cannabis. There's huge opportunity here for treatment - and plenty of ways to make outstanding investments that benefit the companies trying to make the breakthroughs and your portfolio. You are receiving this e-mail at ITS028@gmail.com, as a part of your subscription. Remove your email from this list: Unsubscribe © 2019 The National Institute for Cannabis Investors All Rights Reserved The National Institute for Cannabis Investors | 1125 N Charles Street | Baltimore, MD 21201 Toll Free: 866.260.0361; International: 410.777.8270 Contact Customer Service Website: https://nicinvestors.com Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your financial adviser and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. This information may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of The National Institute for Cannabis Investors, 1125 N Charles Street, Baltimore, MD 21201. Privacy Policy | Terms & Conditions